N Engl J Med (2019) 380:34757
In clinical trials, patients were sometimes allowed to stay at a lower dose for up to 8 weeks if needed to let side effects settle down
SURMONT-5 for weight loss: Wegovy vs
TRIUMPH-4 (28.7% weight loss, knee OA population, December 2025), TRIUMPH-1 (28.3%, general obesity, May 2026), TRANSCEND-T2D-1 (-2.0% HbA1c, 16.8% weight loss, June 2026), TRIUMPH-2 (20.8% weight loss, obesity + diabetes, July 23, 2026), and TRIUMPH-3 (22.6% weight loss, obesity + cardiovascular disease, July 23, 2026) have all reported positive results
The courses have an underlying feel that they are truly on your side and trying to help you be successful